Literature DB >> 17561977

Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial.

Ruben H Willemsen1, Nicolette J T Arends, Willie M Bakker-van Waarde, Maarten Jansen, Edgar G A H van Mil, Jaap Mulder, Roelof J Odink, Maarten Reeser, Ciska Rongen-Westerlaken, Wilhelmina H Stokvis-Brantsma, Johan J J Waelkens, Anita C S Hokken-Koelega.   

Abstract

UNLABELLED: Context Alterations in the GH-IGF-I axis in short small-for-gestational-age (SGA) children might be associated with abnormalities in bone mineral density (BMD) and body composition. In addition, birth weight has been inversely associated with diabetes and cardiovascular disease in adult life. Data on detailed body composition in short SGA children and long-term effects of GH treatment are very scarce.
OBJECTIVE: To investigate effects of long-term GH treatment on body composition and BMD by dual energy X-ray absorptiometry (DXA) in short SGA children.
DESIGN: Longitudinal 6-year GH study with a randomized controlled part for 3 years.
RESULTS: At baseline, fat percentage standard deviation score (SDS) and lumbar spine BMD SDS corrected for height (BMAD(LS) SDS) were significantly lower than zero. Lean body mass (LBM) SDS adjusted for age was also reduced, but LBM adjusted for height (LBM SDS(height)) was not decreased. GH treatment induced a decrease in fat percentage SDS and an increase in BMAD(LS) SDS. LBM SDS(height) remained similar in GH-treated children, but deteriorated in untreated controls. When these untreated controls subsequently started GH treatment, their LBM SDS(height) rapidly normalized to values comparable with zero.
CONCLUSION: During long-term GH treatment in short SGA children, fat percentage SDS decreased and BMAD(LS) SDS increased. These effects of GH treatment were most prominent in children who started treatment at a younger age and in those with greater height gain during GH treatment. LBM SDS(height )remained around 0 SDS in GH-treated children, but declined to low normal values in untreated controls.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561977     DOI: 10.1111/j.1365-2265.2007.02913.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Genetic Analysis and Clinical Presentation in Silver Russell Syndrome.

Authors:  Nikhil Lohiya; Rashmi Lote-Oke; Meenal Agarwal; Nikhil Phadke; Vaman Khadilkar; Anuradha Khadilkar
Journal:  Indian J Pediatr       Date:  2018-07-23       Impact factor: 1.967

Review 2.  Growth hormone treatment in non-growth hormone-deficient children.

Authors:  Sandro Loche; Luisanna Carta; Anastasia Ibba; Chiara Guzzetti
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-03-31

3.  Diagnosis and management of Silver-Russell syndrome: first international consensus statement.

Authors:  Emma L Wakeling; Frédéric Brioude; Oluwakemi Lokulo-Sodipe; Susan M O'Connell; Jennifer Salem; Jet Bliek; Ana P M Canton; Krystyna H Chrzanowska; Justin H Davies; Renuka P Dias; Béatrice Dubern; Miriam Elbracht; Eloise Giabicani; Adda Grimberg; Karen Grønskov; Anita C S Hokken-Koelega; Alexander A Jorge; Masayo Kagami; Agnes Linglart; Mohamad Maghnie; Klaus Mohnike; David Monk; Gudrun E Moore; Philip G Murray; Tsutomu Ogata; Isabelle Oliver Petit; Silvia Russo; Edith Said; Meropi Toumba; Zeynep Tümer; Gerhard Binder; Thomas Eggermann; Madeleine D Harbison; I Karen Temple; Deborah J G Mackay; Irène Netchine
Journal:  Nat Rev Endocrinol       Date:  2016-09-02       Impact factor: 43.330

4.  Growth patterns and the use of growth hormone in the mucopolysaccharidoses.

Authors:  L E Polgreen; B S Miller
Journal:  J Pediatr Rehabil Med       Date:  2010

5.  Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome.

Authors:  Lynda E Polgreen; William Thomas; Paul J Orchard; Chester B Whitley; Bradley S Miller
Journal:  Mol Genet Metab       Date:  2013-12-11       Impact factor: 4.797

Review 6.  The Rationale for Growth Hormone Therapy in Children with Short Stature.

Authors:  Annalisa Deodati; Stefano Cianfarani
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27

7.  Astragalus Extract Mixture HT042 Improves Bone Growth, Mass, and Microarchitecture in Prepubertal Female Rats: A Microcomputed Tomographic Study.

Authors:  Jungbin Song; Sung Hyun Lee; Donghun Lee; Hocheol Kim
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-10       Impact factor: 2.629

Review 8.  Shared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.

Authors:  Carlo L Acerini; David Segal; Sherwin Criseno; Kei Takasawa; Navid Nedjatian; Sebastian Röhrich; Mohamad Maghnie
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-22       Impact factor: 5.555

9.  Height and body mass index in molecularly confirmed Silver-Russell syndrome and the long-term effects of growth hormone treatment.

Authors:  Oluwakemi Lokulo-Sodipe; Eloïse Giabicani; Ana P M Canton; Nawfel Ferrand; Jenny Child; Emma L Wakeling; Gerhard Binder; Irène Netchine; Deborah J G Mackay; Hazel M Inskip; Christopher D Byrne; I Karen Temple; Justin H Davies
Journal:  Clin Endocrinol (Oxf)       Date:  2022-03-21       Impact factor: 3.523

10.  Baseline Body Composition in Prepubertal Short Stature Children with Severe and Moderate Growth Hormone Deficiency.

Authors:  Pawel Matusik; Marta Klesiewicz; Karolina Klos; Martyna Stasiulewicz; Aleksandra Barylak; Patrycja Nazarkiewicz; Ewa Malecka-Tendera
Journal:  Int J Endocrinol       Date:  2016-08-30       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.